Scholar Rock SRRK Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Product | ||||||
| Apitegromab | $20.26M+5.0% | $21.18M+3.7% | $21.36M-5.2% | $27.96M+63.7% | $19.3M+5.8% | |
| Early Research | $1.21M-16.8% | $1.87M+77.9% | $1.13M+91.7% | $2.23M+234% | $1.46M+96.4% | |
| RD Expense Srk181 | $36K-96.8% | $149K-92.1% | $357K-82.7% | $792K-75.7% | $1.11M-59.6% | |
| RD Expense Srk439 | $1.76M-58.9% | $507K-90.5% | $1.61M-42.3% | $2.58M+66.1% | $4.28M+116% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Scholar Rock break its business down?
- Scholar Rock (SRRK) reports research and development expense by product across 4 parts — Apitegromab, Early Research, RD Expense Srk181 and RD Expense Srk439. Each is extracted from the segment footnotes and tracked over time.
- Where does Scholar Rock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Scholar Rock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.